| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-14 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.23 | 7e-11 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-11 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-08 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-07 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |